Search results for "Drug production"
showing 4 items of 4 documents
Do terrorism, organized crime (drug production), and state weakness affect contemporary armed conflicts? An empirical analysis
2015
ABSTRACTIn 2014, the UN Security Council emphasized the dangers of terrorism, criminal activity (especially drug production and trafficking), and state weakness in conflict areas. However, neither policy debates nor scholarly analyses have focussed on the potential impact of these elements on conflict dynamics and characteristics, and the investigated partial relationships have led to inconclusive results. This article explores the presence in armed conflicts of terrorist groups among fighting parties, major drug production (indicating the presence of activities typical of criminal organizations), and state failure in the period 1990–2011. Focussing on intrastate conflicts, this article hig…
Impact of orphan drugs on Latvian budget
2016
Background Number of orphan medicinal products on the market and number of rare disease patients, taking these usually expensive products, are increasing. As a result, budget impact of orphan drugs is growing. This factor, along with the cost-effectiveness of orphan drugs, is often considered in the reimbursement decisions, directly affecting accessibility of rare disease therapies. The current study aims to assess the budget impact of orphan drugs in Latvia. Methods Our study covered a 5-year period, from 2010 to 2014. Impact of orphan drugs on Latvian budget was estimated from the National Health Service’s perspective. It was calculated in absolute values and relative to total pharmaceuti…
Adjuncts for ovarian stimulation: when do we adopt “orphan indications” for approved drugs?
2009
Several drugs, shown to be safe for other uses, have proven to be highly effective adjuncts for ovarian stimulation. The authors evaluate these "orphan" indications and make recommendations so that more patients will benefit from their use.
Rare diseases and orphan drugs: Latvian story
2014
Background Ten years have passed since Latvia became a Member State of the EU in 2004. As a result European regulations, including those related to rare diseases and orphan drugs, have been applied to Latvian legislative system. Orphan diseases have been recognized as a priority area for action in the public health system, though there are significant differences in the national healthcare services for rare diseases among the EU States. This study aims to determine situation in the field of rare diseases in Latvia and compare it with other European countries. Methods We used the national plan for rare diseases, EUCERD reports, Orphanet data, Latvian and European regulations, publicly availa…